Lv1
98 积分 2022-08-12 加入
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
22天前
已完结
Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis
26天前
已完结
Crohn's disease
2个月前
已完结
RISANKIZUMAB IMPROVES SYMPTOMS IN ADULTS WITH CROHN'S DISEASE IN CLINICAL PRACTICE: INITIAL RESULTS FROM THE ASPIRECD STUDY
3个月前
已关闭
MID-TERM OUTCOMES OF RISANKIZUMAB IN REFRACTORY CROHN'S DISEASE: A MULTICENTER REAL-WORLD STUDY IN ANDALUSIA, SPAIN
3个月前
已完结
REAL-WORLD EFFECTIVENESS OF RISANKIZUMAB IN ACHIEVING EARLY TRANSMURAL HEALING IN CROHN'S DISEASE: A PROSPECTIVE SINGLE-CENTER EXPERIENCE
3个月前
已关闭
Therapeutic Efficacy of Risankizumab for Small-Intestinal Lesions in Crohn's Disease: A Retrospective Study Using Double-Balloon Endoscopy
3个月前
已关闭
EFFECTIVENESS AND SAFETY OF RISANKIZUMAB AS INDUCTION THERAPY FOR CROHN'S DISEASE
3个月前
已关闭
Therapeutic Efficacy of Risankizumab for Small-Intestinal Lesions in Crohn's Disease: A Retrospective Study Using Double-Balloon Endoscopy
3个月前
已关闭
皖公网安备34019202002308
